SG11201901203PA - Treatment and sustained virologic remission of hiv infection by antibodies to cd4 in haart stabilized patients - Google Patents
Treatment and sustained virologic remission of hiv infection by antibodies to cd4 in haart stabilized patientsInfo
- Publication number
- SG11201901203PA SG11201901203PA SG11201901203PA SG11201901203PA SG11201901203PA SG 11201901203P A SG11201901203P A SG 11201901203PA SG 11201901203P A SG11201901203P A SG 11201901203PA SG 11201901203P A SG11201901203P A SG 11201901203PA SG 11201901203P A SG11201901203P A SG 11201901203PA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- treatment
- new york
- antibodies
- hiv
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2812—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Communicable Diseases (AREA)
- Biophysics (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662374752P | 2016-08-13 | 2016-08-13 | |
| PCT/US2017/046668 WO2018035001A1 (en) | 2016-08-13 | 2017-08-13 | Treatment and sustained virologic remission of hiv infection by antibodies to cd4 in haart stabilized patients |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201901203PA true SG11201901203PA (en) | 2019-03-28 |
Family
ID=61197201
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10202100268RA SG10202100268RA (en) | 2016-08-13 | 2017-08-13 | Treatment and sustained virologic remission of hiv infection by antibodies to cd4 in haart stabilized patients |
| SG11201901203PA SG11201901203PA (en) | 2016-08-13 | 2017-08-13 | Treatment and sustained virologic remission of hiv infection by antibodies to cd4 in haart stabilized patients |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10202100268RA SG10202100268RA (en) | 2016-08-13 | 2017-08-13 | Treatment and sustained virologic remission of hiv infection by antibodies to cd4 in haart stabilized patients |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US11292839B2 (zh) |
| EP (1) | EP3497133A4 (zh) |
| JP (1) | JP2019534891A (zh) |
| KR (1) | KR20190071677A (zh) |
| CN (1) | CN109996815A (zh) |
| AU (1) | AU2017312887A1 (zh) |
| BR (1) | BR112019002734A2 (zh) |
| CA (1) | CA3033728A1 (zh) |
| MX (1) | MX2019001814A (zh) |
| RU (1) | RU2019106804A (zh) |
| SG (2) | SG10202100268RA (zh) |
| TW (1) | TW201808998A (zh) |
| WO (1) | WO2018035001A1 (zh) |
| ZA (1) | ZA201901374B (zh) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11292839B2 (en) * | 2016-08-13 | 2022-04-05 | Ubi Us Holdings, Llc | Treatment and sustained virologic remission of HIV infection by antibodies to CD4 in HAART stabilized patients |
| SG11202112536UA (en) * | 2019-05-16 | 2021-12-30 | Nanjing Legend Biotech Co Ltd | Engineered immune cells comprising a recognition molecule |
| EP4381081A1 (en) | 2021-08-04 | 2024-06-12 | Sana Biotechnology, Inc. | Use of cd4-targeted viral vectors |
| WO2023114949A1 (en) | 2021-12-16 | 2023-06-22 | Sana Biotechnology, Inc. | Methods and systems of particle production |
| WO2023133595A2 (en) | 2022-01-10 | 2023-07-13 | Sana Biotechnology, Inc. | Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses |
| WO2023150647A1 (en) | 2022-02-02 | 2023-08-10 | Sana Biotechnology, Inc. | Methods of repeat dosing and administration of lipid particles or viral vectors and related systems and uses |
| WO2023193015A1 (en) | 2022-04-01 | 2023-10-05 | Sana Biotechnology, Inc. | Cytokine receptor agonist and viral vector combination therapies |
| WO2024026377A1 (en) | 2022-07-27 | 2024-02-01 | Sana Biotechnology, Inc. | Methods of transduction using a viral vector and inhibitors of antiviral restriction factors |
| WO2024044655A1 (en) | 2022-08-24 | 2024-02-29 | Sana Biotechnology, Inc. | Delivery of heterologous proteins |
| WO2024064838A1 (en) | 2022-09-21 | 2024-03-28 | Sana Biotechnology, Inc. | Lipid particles comprising variant paramyxovirus attachment glycoproteins and uses thereof |
| WO2024119157A1 (en) | 2022-12-02 | 2024-06-06 | Sana Biotechnology, Inc. | Lipid particles with cofusogens and methods of producing and using the same |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4381295A (en) | 1979-04-26 | 1983-04-26 | Ortho Pharmaceutical Corporation | Monoclonal antibody to human helper T cells and methods of preparing same |
| DE3828582A1 (de) | 1988-08-23 | 1990-03-01 | Max Planck Gesellschaft | Monoklonaler antikoerper zur inhibierung der infektion von zellen durch hiv-viren |
| EP0365209A3 (en) | 1988-10-17 | 1990-07-25 | Becton, Dickinson and Company | Anti-leu 3a amino acid sequence |
| JPH0725794B2 (ja) | 1990-03-23 | 1995-03-22 | 呉羽化学工業株式会社 | 新規なペプチド |
| DK0512112T3 (da) | 1990-11-27 | 1997-09-29 | Biogen Inc | Anti-CD4-antistoffer, som blokerer HIV-inducerede syncytier |
| AU3328493A (en) | 1991-12-17 | 1993-07-19 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| JPH06125783A (ja) | 1991-12-28 | 1994-05-10 | Chemo Sero Therapeut Res Inst | 組換え抗ｈｉｖ抗体およびその調製方法 |
| EP0746613B1 (en) | 1994-03-08 | 2006-05-24 | Memorial Sloan-Kettering Cancer Center | Recombinant humanized anti-fb5 antibodies |
| US5961976A (en) | 1996-06-03 | 1999-10-05 | United Biomedical, Inc. | Antibodies against a host cell antigen complex for pre- and post-exposure protection from infection by HIV |
| US5962319A (en) | 1997-05-19 | 1999-10-05 | Bml, Inc. | Human-Th1-specific protein, gene encoding the protein, transformants, recombinant vectors, and antibodies related to the gene |
| JP3231262B2 (ja) | 1996-06-05 | 2001-11-19 | 株式会社ビー・エム・エル | ヒトＴｈ１特異的タンパク質及びこれをコードする遺伝子、並びにこれに関連する形質転換体、組換えベクター及び抗体 |
| JPH10155489A (ja) | 1996-11-27 | 1998-06-16 | Asahi Chem Ind Co Ltd | 組換え抗体及びそれをコードする核酸 |
| DE69833755T2 (de) | 1997-05-21 | 2006-12-28 | Biovation Ltd. | Verfahren zur herstellung von nicht-immunogenen proteinen |
| CN1307640A (zh) | 1998-05-25 | 2001-08-08 | 旭化成株式会社 | 细胞分离装置和分离方法 |
| US6090388A (en) | 1998-06-20 | 2000-07-18 | United Biomedical Inc. | Peptide composition for prevention and treatment of HIV infection and immune disorders |
| WO2000051631A2 (en) | 1999-03-02 | 2000-09-08 | Schering Corporation | Pegylated alpha interferon for hiv therapy |
| AU2002356638A1 (en) | 2001-12-11 | 2003-06-23 | Biotectid Gmbh | Use of a labeled ligand having human cd4 specificity |
| JP2003327536A (ja) | 2002-03-07 | 2003-11-19 | Kitasato Inst:The | ヒト免疫不全症候群ウイルスの感染、増殖抑制剤 |
| US20030211470A1 (en) | 2002-03-15 | 2003-11-13 | Olson William C. | CD4-IgG2-based salvage therapy of HIV-1 infection |
| US7501494B2 (en) | 2003-01-15 | 2009-03-10 | United Biomedical, Inc. | Designed deimmunized monoclonal antibodies for protection against HIV exposure and treatment of HIV infection |
| RU2393873C2 (ru) | 2005-05-02 | 2010-07-10 | Майметикс Корпорейшн | Антитело или его фрагмент, имеющие нейтрализующую активность в отношении вич, но не в отношении il2 |
| JP5020941B2 (ja) | 2005-05-02 | 2012-09-05 | マイメティクス コーポレーション | Ｈｉｖに対して中和活性を有するがｉｌ２には中和活性を有さない抗体又はその断片 |
| US20090214569A1 (en) | 2005-08-25 | 2009-08-27 | Government Of The Us, As Represented By The Secretary, Dept. Of Health & Human Services | Use of HIV envelope/CD4 complexes for the generation antibodies |
| WO2007094983A2 (en) | 2006-02-03 | 2007-08-23 | Tanox, Inc. | Methods and compositions for the inhibition of hiv infection of t cells |
| EP2892561A1 (en) | 2012-09-07 | 2015-07-15 | Baylor Research Institute | Hiv vaccine compositions and methods |
| US9908938B2 (en) | 2013-03-14 | 2018-03-06 | Macrogenics, Inc. | Bispecific molecules that are immunoreactive with immune effector cells that express an activating receptor and an antigen expressed by a cell infected by a virus and uses thereof |
| JP2016519166A (ja) * | 2013-05-24 | 2016-06-30 | クーパー ヒューマン システムズ エルエルシー | Ｈｉｖ感染症を処置するための方法および組成物 |
| WO2016043788A1 (en) | 2014-09-16 | 2016-03-24 | United Biomedical, Inc | Treatment and functional cure of hiv infection by monoclonal antibodies to cd4 mediating competitive hiv entry inhibition |
| US11292839B2 (en) * | 2016-08-13 | 2022-04-05 | Ubi Us Holdings, Llc | Treatment and sustained virologic remission of HIV infection by antibodies to CD4 in HAART stabilized patients |
-
2017
- 2017-08-13 US US16/325,361 patent/US11292839B2/en active Active
- 2017-08-13 SG SG10202100268RA patent/SG10202100268RA/en unknown
- 2017-08-13 CA CA3033728A patent/CA3033728A1/en active Pending
- 2017-08-13 MX MX2019001814A patent/MX2019001814A/es unknown
- 2017-08-13 SG SG11201901203PA patent/SG11201901203PA/en unknown
- 2017-08-13 KR KR1020197007296A patent/KR20190071677A/ko not_active Application Discontinuation
- 2017-08-13 WO PCT/US2017/046668 patent/WO2018035001A1/en unknown
- 2017-08-13 RU RU2019106804A patent/RU2019106804A/ru not_active Application Discontinuation
- 2017-08-13 BR BR112019002734-3A patent/BR112019002734A2/pt unknown
- 2017-08-13 AU AU2017312887A patent/AU2017312887A1/en active Pending
- 2017-08-13 JP JP2019529466A patent/JP2019534891A/ja active Pending
- 2017-08-13 EP EP17841919.8A patent/EP3497133A4/en active Pending
- 2017-08-13 CN CN201780050119.1A patent/CN109996815A/zh active Pending
- 2017-08-14 TW TW106127443A patent/TW201808998A/zh unknown
-
2019
- 2019-03-05 ZA ZA2019/01374A patent/ZA201901374B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| BR112019002734A2 (pt) | 2019-05-14 |
| KR20190071677A (ko) | 2019-06-24 |
| RU2019106804A (ru) | 2020-09-21 |
| TW201808998A (zh) | 2018-03-16 |
| ZA201901374B (en) | 2022-04-28 |
| CA3033728A1 (en) | 2018-02-22 |
| EP3497133A1 (en) | 2019-06-19 |
| RU2019106804A3 (zh) | 2021-03-29 |
| WO2018035001A1 (en) | 2018-02-22 |
| CN109996815A (zh) | 2019-07-09 |
| JP2019534891A (ja) | 2019-12-05 |
| US11292839B2 (en) | 2022-04-05 |
| US20190194326A1 (en) | 2019-06-27 |
| EP3497133A4 (en) | 2020-03-25 |
| MX2019001814A (es) | 2019-07-08 |
| SG10202100268RA (en) | 2021-02-25 |
| AU2017312887A1 (en) | 2019-03-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201901203PA (en) | Treatment and sustained virologic remission of hiv infection by antibodies to cd4 in haart stabilized patients | |
| SG11201805320XA (en) | Materials and methods for treatment of amyotrophic lateral sclerosis and/or frontal temporal lobular degeneration | |
| SG11201909547TA (en) | Pharmaceutical composition comprising bispecific antibody constructs for improved storage and administration | |
| SG11201909322VA (en) | Treatment of asthma with anti-tslp antibody | |
| SG11201810423XA (en) | Pd-1 / pd-l1 inhibitors for cancer treatment | |
| SG11201806863WA (en) | Tetracyclic pyridone compounds as antivirals | |
| SG11201903882VA (en) | Il-2 variants for the treatment of autoimmune diseases | |
| SG11201808990QA (en) | Compositions for topical application of compounds | |
| SG11201909949XA (en) | Targeted immunotolerance | |
| SG11201901950TA (en) | Methods of treating immune disorders using pd-1 binding proteins | |
| SG11201900844UA (en) | Amino pyrimidine ssao inhibitors | |
| SG11201907583TA (en) | Methods for treating complement-mediated diseases and disorders | |
| SG11201804814YA (en) | Materials and methods for delivering nucleic acids to cochlear and vestibular cells | |
| SG11201906386XA (en) | Combination therapy involving diaryl macrocyclic compounds | |
| SG11201810525XA (en) | Anti-gitr antibodies and uses thereof | |
| SG11201803906PA (en) | Control of cellular redox levels | |
| SG11201909155VA (en) | Ask1 inhibitor compounds and uses thereof | |
| SG11201808125RA (en) | Methods for solid tumor treatment | |
| SG11201407580YA (en) | Composition comprising two antibodies engineered to have reduced and increased effector function | |
| SG11201805001UA (en) | Method of treating influenza a | |
| SG11201901961SA (en) | Methods of using a bispecific antibody that recognizes coagulation factor ix and/or activated coagulation factor ix and coagulation factor x and/or activated coagulation factor x | |
| SG11201909019SA (en) | Methods of treatment using a jak inhibitor compound | |
| SG11201809908TA (en) | Stabilized glycopeptide antibiotic formulations | |
| SG11201909680UA (en) | Phenyl-2-hydroxy-acetylamino-2-methyl-phenyl compounds | |
| SG11201810454YA (en) | Use of an anti-pd-1 antibody in combination with an anti-cd30 antibody in lymphoma treatment |